Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF1LYP)

Drug Name

A204 Drug Info

Synonyms

Antibiotic A 204A; A 204; 12750-79-7; Antibiotic A204; A204; Antibiotic A 204-I; A 204A; AKOS040747641; 43110-10-7; 2-(2-hydroxy-6-((2-(5'-(6-hydroxy-4-methoxy-3,5,6-trimethyltetrahydro-2H-pyran-2-yl)octahydro-[2,2'-bifuran]-5-yl)-3,9-dimethoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-7-yl)methyl)-5-methoxy-4-((5-methoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3,5-dimethyltetrahydro-2H-pyran-2-yl)propanoic acid; 2-[2-hydroxy-6-[[2-[5-[5-(6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl)oxolan-2-yl]oxolan-2-yl]-3,7-dimethoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]methyl]-5-methoxy-4-(5-methoxy-6-methyloxan-2-yl)oxy-3,5-dimethyloxan-2-yl]propanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B virus infection	1E51.0	Phase 1	[1]

Cross-matching ID

PubChem CID: 206186
TTD Drug ID: DMF1LYP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis B virus Capsid protein (HBV C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-56136379	DM9RW6H	Hepatitis B	1E51	Phase 2	[2]
ABI-H2158	DM6X70G	Hepatitis B	1E51	Phase 2	[3]
ABI-H0731	DMX1KDM	Hepatitis B	1E51	Phase 2	[4]
ABI-H3733	DM4TN6W	Hepatitis B	1E51	Phase 1	[3]
EDP-514	DM8KRA3	Chronic HBV infection	1E51.0Z	Phase 1	[5]
RG7907	DMKVIS5	Hepatitis B	1E51	Phase 1	[6]
ZM-H1505R	DMX6AJ8	Hepatitis B	1E51	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis B virus Capsid protein (HBV C)	TTM42UJ	CAPSD_HBVD3	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Klus Pharma
2	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9.
3	Clinical pipeline report, company report or official report of Assembly Biosciences.
4	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.
5	Clinical pipeline report, company report or official report of Enanta Pharmaceuticals.
6	Clinical pipeline report, company report or official report of Roche.
7	Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma.